In 1953, cardiologists and scientists of Harvard University developed a principle of “phase shift diastolic augmentation”. This principle proved that the pressure on the heart during the palpitation could be reduced to prevent a heart attack. On this principle, External Enhanced Counterpulsation (EECP) developed. Because of the Harvard University research, heart surgery can be avoided by this EECP treatment. About a million heart patients across the globe have benefited from EECP treatment. It has been approved by US Food and Drugs Administration (USFDA), which regulates validity of medicines, machines and different ways of treatment world over Around 15,000 machines are carrying out EECP in the USA, UK, China and other European countries. Over 50,000 patients have been treated in India by the EECP treatment.